One of the major roadblocks to human tissue engineering has been the ability to vascularize tissue, confining the majority of tissue creation to that which doesn’t have a strong blood supply in the body. The team at Aspect Biosystems, however, is working to change this by developing innovative strategies and opening their platform to collaborative efforts with academic partners around the world.

For instance, they’ve partnered with UCLA in the development of new vascular technology as well as researchers around the globe who are working on the creation of kidney and skin tissues.

Tamer Mohamed is the CEO of Aspect Biosystems and joins the conversation today to discuss all of this and more, including their muscle portfolio composed of intestinal, cardiac, and smooth muscle tissue, liver drug testing platform, and pancreatic tissue program for the treatment of type 1 diabetes. He also explains the ins and out of the technology behind their work, and what to look forward to in the near future.

Press play for the full conversation and learn more by visiting aspectbiosystems.com.